Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.2 USD | 0.00% | +0.98% | -8.63% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 9.53M | Capitalization | 169M |
---|---|---|---|---|---|
Net income 2024 * | -121M | Net income 2025 * | -64M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 17.7 x |
P/E ratio 2024 * |
-1.43
x | P/E ratio 2025 * |
-3.23
x | Employees | 24 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 62.99% |
Latest transcript on Outlook Therapeutics, Inc.
1 day | +0.14% | ||
1 week | +0.98% | ||
Current month | +1.84% | ||
1 month | -16.28% | ||
3 months | -9.04% | ||
6 months | -19.86% | ||
Current year | -8.63% |
Managers | Title | Age | Since |
---|---|---|---|
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Lawrence Kenyon
DFI | Director of Finance/CFO | 58 | 15-09-14 |
Surendra Sharma
CTO | Chief Tech/Sci/R&D Officer | - | 23-01-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Randy Thurman
CHM | Chairman | 74 | 18-04-12 |
Kurt Hilzinger
BRD | Director/Board Member | 63 | 15-12-10 |
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +10.33% | - | |
0.00% | 17 M€ | +4.59% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 7.2 | +0.14% | 133,839 |
24-06-04 | 7.19 | +2.71% | 265,769 |
24-06-03 | 7 | -0.99% | 227,818 |
24-05-31 | 7.07 | -2.08% | 166,606 |
24-05-30 | 7.22 | +1.26% | 233,461 |
Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.63% | 169M | |
+55.70% | 59.34B | |
+41.08% | 40.24B | |
-5.39% | 39.88B | |
-5.56% | 28.55B | |
+16.46% | 27.26B | |
-20.56% | 19.23B | |
+33.03% | 12.61B | |
+25.85% | 12.28B | |
+2.72% | 12.49B |
- Stock Market
- Equities
- OTLK Stock